Cerity Partners LLC Makes New Investment in Immunome, Inc. (NASDAQ:IMNM)

Cerity Partners LLC acquired a new stake in shares of Immunome, Inc. (NASDAQ:IMNM) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 61,346 shares of the company’s stock, valued at approximately $656,000.

Several other institutional investors have also modified their holdings of the business. Dorsey Wright & Associates acquired a new stake in Immunome during the 3rd quarter worth approximately $26,000. Acadian Asset Management LLC bought a new stake in shares of Immunome during the third quarter worth $414,000. Finally, TD Asset Management Inc acquired a new stake in shares of Immunome during the third quarter worth $1,063,000. Institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on IMNM shares. SVB Leerink assumed coverage on Immunome in a report on Monday, January 29th. They set an “outperform” rating and a $30.00 target price for the company. Wedbush increased their price objective on Immunome from $27.00 to $33.00 and gave the stock an “outperform” rating in a report on Monday, April 1st. Guggenheim assumed coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. Finally, Leerink Partnrs reaffirmed an “outperform” rating on shares of Immunome in a research report on Monday, January 29th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $32.67.

Immunome Price Performance

Immunome stock opened at $14.66 on Wednesday. The company has a market cap of $875.06 million, a price-to-earnings ratio of -2.72 and a beta of 1.66. The firm has a 50-day moving average of $22.56 and a 200-day moving average of $15.07. Immunome, Inc. has a one year low of $4.44 and a one year high of $30.96.

Immunome (NASDAQ:IMNM) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.54) EPS for the quarter, missing the consensus estimate of ($0.28) by ($0.26). The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $3.40 million. Immunome had a negative net margin of 761.92% and a negative return on equity of 69.74%. As a group, sell-side analysts expect that Immunome, Inc. will post -1.91 earnings per share for the current year.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.